REFERENCES
1. Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
2. Chiu RWK, Chan KCA, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA 2008;105:20458-63.
3. van der Meij KR, Sistermans EA, Macville MV, et al. TRIDENT-2: national implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the netherlands. Am J Hum Genet 2019;105:1091-101.
4. Chan KCA, Jiang P, Chan CWM, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA 2013;110:18761-8.
5. Chan KA, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013;59:211-24.
6. Jiang P, Chan CWM, Chan KCA, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci USA 2015:112.
7. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017;9:eaan2415.
8. Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science 2021;372:eaaw3616.
9. Yu SCY, Jiang P, Chan KCA, et al. Combined count- and size-based analysis of maternal plasma DNA for noninvasive prenatal detection of fetal subchromosomal aberrations facilitates elucidation of the fetal and/or maternal origin of the aberrations. Clin Chem 2017;63:495-502.
10. Lo YMD, Chan KCA, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010:2.
11. Zheng YWL, Chan KCA, Sun H, et al. Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model. Clin Chem 2012;58:549-58.
12. Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med 2018;10:eaat4921.
13. Chan RWY, Jiang P, Peng X, et al. Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing. Proc Natl Acad Sci USA 2014:111.
14. Underhill HR, Kitzman JO, Hellwig S, et al. Fragment length of circulating tumor DNA. PLoS Genet 2016;12:e1006162.
15. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102:16368-73.
16. Yu SCY, Chan KCA, Zheng YWL, et al. Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing. Proc Natl Acad Sci USA 2014;111:8583-8.
17. Kitzman JO, Snyder MW, Ventura M, et al. Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med 2012:4.
18. Chan KCA, Jiang P, Sun K, et al. Second generation noninvasive fetal genome analysis reveals de novo mutations, single-base parental inheritance, and preferred DNA ends. Proc Natl Acad Sci USA 2016:113.
19. Marass F, Stephens D, Ptashkin R, et al. Fragment size analysis may distinguish clonal hematopoiesis from tumor-derived mutations in cell-free DNA. Clin Chem 2020;66:616-8.
20. Straver R, Oudejans CBM, Sistermans EA, Reinders MJT. Calculating the fetal fraction for noninvasive prenatal testing based on genome-wide nucleosome profiles. Prenat Diagn 2016;36:614-21.
21. Snyder M, Kircher M, Hill A, Daza R, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016;164:57-68.
22. Esfahani MS, Hamilton EG, Mehrmohamadi M, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol 2022;40:585-97.
23. Chan D, Lam W, Hui E, et al. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein–Barr virus DNA in post-treatment plasma. Ann Oncol 2022;33:794-803.
24. Meriranta L, Alkodsi A, Pasanen A, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood 2022;139:1863-77.
25. Vong JSL, Tsang JCH, Jiang P, et al. Single-Stranded DNA library preparation preferentially enriches short maternal DNA in maternal plasma. Clin Chem 2017;63:1031-7.
26. Burnham P, Kim MS, Agbor-enoh S, et al. Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. Sci Rep 2016:6.
27. Hudecova I, Smith CG, Hänsel-hertsch R, et al. Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. Genome Res 2022;32:215-27.
28. Cheng J, Morselli M, Huang W, et al. Plasma contains ultrashort single-stranded DNA in addition to nucleosomal cell-free DNA. iScience 2022;25:104554.
29. Sin STK, Jiang P, Deng J, et al. Identification and characterization of extrachromosomal circular DNA in maternal plasma. Proc Natl Acad Sci USA 2020;117:1658-65.
30. Sin ST, Deng J, Ji L, et al. Effects of nucleases on cell-free extrachromosomal circular DNA. JCI Insight 2022;7:e156070.
31. Tse OYO, Jiang P, Cheng SH, et al. Genome-wide detection of cytosine methylation by single molecule real-time sequencing. Proc Natl Acad Sci USA 2021:118.
32. Yu SCY, Jiang P, Peng W, et al. Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma. Proc Natl Acad Sci USA 2021:118.
33. Yu SCY, Deng J, Qiao R, et al. Comparison of Single Molecule, Real-Time Sequencing and Nanopore Sequencing for Analysis of the Size, End-Motif, and Tissue-of-Origin of Long Cell-Free DNA In plasma. Clin Chem ;2022:hvac180.
34. Tan G, Opitz L, Schlapbach R, Rehrauer H. Long fragments achieve lower base quality in Illumina paired-end sequencing. Sci Rep 2019;9:2856.
35. Head SR, Komori HK, LaMere SA, et al. Library construction for next-generation sequencing: overviews and challenges. Biotechniques 2014;56:61-4, 66, 68, passim.
36. Choy LYL, Peng W, Jiang P, et al. Single-molecule sequencing enables long cell-free DNA detection and direct methylation analysis for cancer patients. Clin Chem 2022;68:1151-63.
37. Jiang P, Sun K, Tong YK, et al. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proc Natl Acad Sci USA 2018;115:E10925-33.
38. Bao H, Wang Z, Ma X, et al. Letter to the Editor: an ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection. Mol Cancer 2022;21:129.
39. Suzuki N, Kamataki A, Yamaki J, Homma Y. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta 2008;387:55-8.
40. Chandrananda D, Thorne NP, Bahlo M. High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Med Genomics 2015;8:29.
41. Serpas L, Chan RWY, Jiang P, et al. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proc Natl Acad Sci USA 2019;116:641-9.
42. Han DSC, Ni M, Chan RWY, et al. The biology of cell-free DNA fragmentation and the roles of DNASE1, DNASE1L3, and DFFB. Am J Hum Genet 2020;106:202-14.
43. Jiang P, Sun K, Peng W, et al. Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation. Cancer Discov 2020;10:664-73.
44. Zhitnyuk YV, Koval AP, Alferov AA, et al. Deep cfDNA fragment end profiling enables cancer detection. Mol Cancer 2022;21:26.
45. Guo W, Chen X, Liu R, et al. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine 2022;81:104131.
46. Chan RWY, Serpas L, Ni M, et al. Plasma DNA profile associated with DNASE1L3 gene mutations: clinical observations, relationships to nuclease substrate preference, and in vivo correction. Am J Hum Genet 2020;107:882-94.
47. Jiang P, Xie T, Ding SC, et al. Detection and characterization of jagged ends of double-stranded DNA in plasma. Genome Res 2020;30:1144-53.
48. Ding SC, Chan RWY, Peng W, et al. Jagged ends on multinucleosomal cell-free DNA serve as a biomarker for nuclease activity and systemic lupus erythematosus. Clin Chem 2022;68:917-26.
49. Ma ML, Zhang H, Jiang P, et al. Topologic analysis of plasma mitochondrial DNA reveals the coexistence of both linear and circular molecules. Clin Chem 2019;65:1161-70.
50. Ma ML, Yakovenko S, Zhang H, et al. Fetal mitochondrial DNA in maternal plasma in surrogate pregnancies: detection and topology. Prenat Diagn 2021;41:368-75.
51. Sin STK, Ji L, Deng J, et al. Characteristics of fetal extrachromosomal circular DNA in maternal plasma: methylation status and clearance. Clin Chem 2021;67:788-96.
52. Kumar P, Dillon LW, Shibata Y, Jazaeri AA, Jones DR, Dutta A. Normal and cancerous tissues release extrachromosomal circular DNA (eccDNA) into the circulation. Mol Cancer Res 2017;15:1197-205.
53. Paulsen T, Kumar P, Koseoglu MM, Dutta A. Discoveries of extrachromosomal circles of DNA in normal and tumor cells. Trends Genet 2018;34:270-8.
54. Tsui NB, Jiang P, Chow KC, et al. High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS One 2012;7:e48319.
55. Zhang J, Tong KL, Li PK, et al. Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: urinary DNA chimerism. Clin Chem 1999;45:1741-6.
56. Chen M, Chan RWY, Cheung PPH, et al. Fragmentomics of urinary cell-free DNA in nuclease knockout mouse models. PLoS Genet 2022;18:e1010262.
57. Cheng THT, Jiang P, Tam JCW, et al. Genomewide bisulfite sequencing reveals the origin and time-dependent fragmentation of urinary cfDNA. Clin Biochem 2017;50:496-501.
58. Cheng THT, Jiang P, Teoh JYC, et al. Noninvasive detection of bladder cancer by shallow-depth genome-wide bisulfite sequencing of urinary cell-free DNA for methylation and copy number profiling. Clin Chem 2019;65:927-36.
59. Zhou Z, Cheng SH, Ding SC, et al. Jagged ends of urinary cell-free DNA: characterization and feasibility assessment in bladder cancer detection. Clin Chem 2021;67:621-30.
60. Xie T, Wang G, Ding SC, et al. High-resolution analysis for urinary DNA jagged ends. NPJ Genom Med 2022;7:14.
61. Burke DM, Shackley DC, O’Reilly PH. The community-based morbidity of flexible cystoscopy. BJU Int 2002;89:347-9.
62. Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014;66:253-62.
63. Ou Z, Li K, Yang T, et al. Detection of bladder cancer using urinary cell-free DNA and cellular DNA. Clin Transl Med 2020;9:4.
64. Birkenkamp-Demtröder K, Nordentoft I, Christensen E, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 2016;70:75-82.
65. Mouliere F, Smith CG, Heider K, et al. Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. EMBO Mol Med 2021;13:e12881.
66. Wu X, Xing P, Shi M, et al. Cerebrospinal fluid cell-free DNA-based detection of high level of genomic instability is associated with poor prognosis in NSCLC patients with leptomeningeal metastases. Front Oncol 2022;12:664420.
67. Lo YMD, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
68. Chan KCA, Woo JKS, King A, et al. Analysis of plasma epstein-barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 2017;377:513-22.
69. Lam WKJ, Jiang P, Chan KCA, et al. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc Natl Acad Sci USA 2018;115:E5115-24.
70. Linthorst J, Welkers MRA, Sistermans EA. Distinct fragmentation patterns of circulating viral cell-free DNA in 83,552 non-invasive prenatal testing samples. Extracell Vesicles Circ Nucleic Acids 2021; doi: 10.20517/evcna.2021.13.
71. Lui YY, Chik KW, Chiu RW, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002;48:421-7.
72. Sun K, Jiang P, Chan KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci USA 2015;112:E5503-12.
73. Moss J, Magenheim J, Neiman D, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun 2018;9:5068.
74. Gai W, Zhou Z, Agbor-Enoh S, et al. Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology. Elife 2021:10.
75. Lam NY, Rainer TH, Chiu RW, Lo YM. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem 2004;50:256-7.
76. Fernando MR, Chen K, Norton S, et al. A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. Prenat Diagn 2010;30:418-24.
77. Hisano O, Ito T, Miura F. Short single-stranded DNAs with putative non-canonical structures comprise a new class of plasma cell-free DNA. BMC Biol 2021;19:225.
